US HIV Diagnostics Market: Innovation in Pre-Exposure Prophylaxis (PrEP) Testing and Point-of-Care Solutions
The US HIV Diagnostics Market is a highly developed and mature sector, continuously evolving due to changes in treatment paradigms and public health goals, specifically the initiative to end the HIV epidemic. Market growth is heavily influenced by the widespread adoption of routine screening, improved testing sensitivity and accuracy, and the demand generated by Pre-Exposure Prophylaxis (PrEP). PrEP, a prevention strategy where people at high risk of HIV take daily medication, requires frequent HIV testing to ensure the person is HIV-negative before and during treatment, creating a significant and recurring volume of diagnostic demand.
